BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28511384)

  • 1. Community Acquired
    Ranjan R; Chowdhary P; Kamra A
    J Clin Diagn Res; 2017 Mar; 11(3):DD01-DD02. PubMed ID: 28511384
    [No Abstract]   [Full Text] [Related]  

  • 2. A rare case of community acquired Burkholderia cepacia infection presenting as pyopneumothorax in an immunocompetent individual.
    Karanth SS; Regunath H; Chawla K; Prabhu M
    Asian Pac J Trop Biomed; 2012 Feb; 2(2):166-8. PubMed ID: 23569891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An opportunistic pathogen frequently isolated from immunocompromised patients: Burkholderia cepacia complex].
    Baylan O
    Mikrobiyol Bul; 2012 Apr; 46(2):304-18. PubMed ID: 22639321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.
    Horsley A; Jones AM
    Cochrane Database Syst Rev; 2012 Oct; 10():CD009529. PubMed ID: 23076960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burkholderia cepacia complex infection in an Adult Cystic Fibrosis unit in Madrid.
    Correa-Ruiz A; Girón R; Buendía B; Medina-Pascual MJ; Valenzuela C; López-Brea M; Sáez-Nieto JA
    Enferm Infecc Microbiol Clin; 2013 Dec; 31(10):649-54. PubMed ID: 23528342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of bacteraemia caused by Burkholderia cepacia complex species and antimicrobial susceptibility of the isolates in a medical centre in Taiwan.
    Chien YC; Liao CH; Sheng WH; Chien JY; Huang YT; Yu CJ; Hsueh PR
    Int J Antimicrob Agents; 2018 Mar; 51(3):357-364. PubMed ID: 28705667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant
    Saran S; Azim A; Gurjar M
    Int J Crit Illn Inj Sci; 2018; 8(3):173-175. PubMed ID: 30181976
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case Report of Necrotizing Pneumonia Due to Burkholderia cepacia Syndrome.
    Hedary AS; DeBord NL; Marshall D
    Cureus; 2024 Jan; 16(1):e52955. PubMed ID: 38406162
    [No Abstract]   [Full Text] [Related]  

  • 9. Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: A review of adult and pediatric literature.
    Abdallah M; Abdallah HA; Memish ZA
    Infez Med; 2018 Dec; 26(4):299-307. PubMed ID: 30555132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
    Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
    Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cepacia Syndrome in a Non-Cystic Fibrosis Patient.
    Hauser N; Orsini J
    Case Rep Infect Dis; 2015; 2015():537627. PubMed ID: 26357579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Burkholderia cepacia: dangers of a phytopathogen organism for patients with cystic fibrosis].
    Segonds C; Chabanon G
    Ann Biol Clin (Paris); 2001; 59(3):259-69. PubMed ID: 11397673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accurate identification of members of the Burkholderia cepacia complex in cystic fibrosis sputum.
    Martinucci M; Roscetto E; Iula VD; Votsi A; Catania MR; De Gregorio E
    Lett Appl Microbiol; 2016 Mar; 62(3):221-9. PubMed ID: 26671758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.
    Jones AM; Dodd ME; Govan JR; Barcus V; Doherty CJ; Morris J; Webb AK
    Thorax; 2004 Nov; 59(11):948-51. PubMed ID: 15516469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data on antibacterial activity of Echinacea purpurea-associated bacterial communities against Burkholderia cepacia complex strains, opportunistic pathogens of Cystic Fibrosis patients.
    Chiellini C; Maida I; Maggini V; Bosi E; Mocali S; Emiliani G; Perrin E; Firenzuoli F; Mengoni A; Fani R
    Microbiol Res; 2017 Mar; 196():34-43. PubMed ID: 28164789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burkholderia cepacia complex: beyond pseudomonas and acinetobacter.
    Gautam V; Singhal L; Ray P
    Indian J Med Microbiol; 2011; 29(1):4-12. PubMed ID: 21304187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
    Kitt H; Lenney W; Gilchrist FJ
    BMC Pharmacol Toxicol; 2016 Mar; 17():14. PubMed ID: 27018049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkholderia cepacia Complex Vaccines: Where Do We Go from here?
    Pradenas GA; Ross BN; Torres AG
    Vaccines (Basel); 2016 Apr; 4(2):. PubMed ID: 27092530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.
    Garcia BA; Carden JL; Goodwin DL; Smith TA; Gaggar A; Leon K; Antony VB; Rowe SM; Solomon GM
    BMC Pulm Med; 2018 Feb; 18(1):35. PubMed ID: 29444656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.